Trial Profile
Randomized Multicenter Phase III Study Comparing the Rate of Molecular Response 4.5 at 12 Months in Newly Diagnosed Philadelphia Positive Chronic Phase Chronic Myelogenous Leukemia Patients Receiving Either Frontline Nilotinib 600 mg Daily or Nilotinib 600 mg Daily Combined to Pegylated Interferon-alfa 2a (Peg-IFN)
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 31 Mar 2023
Price :
$35
*
At a glance
- Drugs Nilotinib (Primary) ; Peginterferon alfa-2a (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- Acronyms PETALs
- 31 Mar 2023 This trial has been completed (End Date: 21 Oct 2022), according to European Clinical Trials Database record.
- 14 Dec 2021 Results (n=200)presented at the 63rd American Society of Hematology Annual Meeting and Exposition
- 06 Nov 2019 Results released at the 61st Annual Meeting and Exposition of the American Society of Hematology